Kaitlyn Bader, Assistant Managing Editor

At Horizons in Advanced Practice, Douglas DiRuggiero, DMSc, MHS, PA-C, reviewed oral and targeted psoriasis therapies and shared decision-making.

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, discusses the Horizons in Advanced Practice meeting, oral peptides in psoriasis, and JAK inhibitors in hidradenitis suppurativa.

At the 2026 Horizons in Advanced Practice meeting, Omar Noor, MD, discussed viewing atopic dermatitis patients as type 2 inflammatory patients, growth curve data, and recent hidradenitis suppurativa guidelines.

The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.

Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.

Benjamin Ungar, MD, moderated a recent Dermatology Times Case-Based Roundtable event on how to define severity, choose among JAK inhibitors, and monitor patients with alopecia areata.

Clinicians at a Dermatology Times Case-Based Roundtable, moderated by Chesahna Kindred, MD, debated when to escalate to oral JAK inhibitors for alopecia areata and how to counsel patients on timing, monitoring, and safety.

Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.

Angela Fitch, MD, co-founder and chief medical officer of Knownwell, discussed GLP-1 access strategies and a proposed randomized trial in hidradenitis suppurativa at Fall Clinical 2026.

At Fall Clinical 2026, Joel Gelfand, MD, MSCE, reviewed GLP-1 candidacy, weight conversations, and an upcoming monotherapy trial in psoriasis.

A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.

Disc Medicine reports the phase 3 APOLLO trial met all primary and secondary end points, with whole-blood PPIX reduced 41.4% vs placebo and an NDA resubmission planned by end of 2026.

At Fall Clinical 2026, Angela Fitch, MD, discussed GLP-1 prescribing by dermatologists and the metabolic and inflammatory link to psoriasis.

Joel Gelfand, MD, MSCE, discussed the role of GLP-1 agonists in addressing the metabolic comorbidities of psoriatic disease at Fall Clinical 2026.

The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.

On this episode of Don’t Be Rash, host Andrew C. Krakowski, MD, welcomes Lawrence Eichenfield, MD, pediatric dermatologist, to discuss topical corticosteroid potency, dosing, and where they fit alongside nonsteroidal agents.

Christopher Bunick, MD, PhD, reviews data on investigational atopic dermatitis agents presented at EADV 2026 and biomarker findings for upadacitinib.

At Fall Clinical 2026, Todd Schlesinger, MD, explained recent exosome regulatory progress, the remibrutinib label update for symptomatic dermographism, and ongoing clinical trials at his trial center.

In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.

Along with her Fall Clinical 2026 sessions, Glynis Ablon, MD, discusses combining energy devices with PRP and exosomes, early extended release minoxidil results, and topical stem cell research.

Todd Schlesinger, MD, highlighted the new photodynamic therapy indication for superficial basal cell carcinoma, immunotherapy options for cutaneous squamous cell carcinoma, and sequential actinic keratosis therapy at Fall Clinical 2026.

Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.

At Fall Clinical 2026, Aaron Farberg, MD, reviewed gene expression profiling in atopic dermatitis and melanoma, and the Ameluz plus PDT approval for superficial basal cell carcinoma.

At Fall Clinical 2026, Neal Bhatia, MD, discussed cycle therapy for actinic keratosis, red light photodynamic therapy for superficial basal cell carcinoma, and clinical research pitfalls

Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.

In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.

At Fall Clinical 2026, Christopher Bunick, MD, PhD, discussed topical and oral acne management, including tetracycline selection and micronized isotretinoin.

At Fall Clinical 2026, Glynis Ablon, MD, recommends body dysmorphic disorder screening and systematic documentation in aesthetics, plus early combination therapy for multifactorial alopecia.

At Fall Clinical 2026, Shannon Trotter, DO, reviews locally advanced and metastatic cutaneous squamous cell carcinoma, immune checkpoint inhibitors, and proposed Medicare cuts affecting skin cancer care.

Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.